Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence.
about
Radiation Therapy after Radical Prostatectomy: Implications for CliniciansMicroRNA as new tools for prostate cancer risk assessment and therapeutic intervention: results from clinical data set and patients' samplesEvolving transcriptomic fingerprint based on genome-wide data as prognostic tools in prostate cancerPost-treated prostate cancer: normal findings and signs of local relapse on multiparametric magnetic resonance imaging.Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population.Overdetection of recurrence after radical prostatectomy: estimates based on patient and tumor characteristicsExpected population impacts of discontinued prostate-specific antigen screening.Prognostic Factors for Prostate Cancer Endpoints Following Biochemical Failure: A Review of the Literature.Low detectable prostate specific antigen after radical prostatectomy--treat or watch?Identification of differentially expressed proteins in direct expressed prostatic secretions of men with organ-confined versus extracapsular prostate cancer.A single nucleotide polymorphism in ADIPOQ predicts biochemical recurrence after radical prostatectomy in localized prostate cancer.Prostate cancer mortality following active surveillance versus immediate radical prostatectomy.Low β₂-adrenergic receptor level may promote development of castration resistant prostate cancer and altered steroid metabolism.A prostate-specific antigen doubling time of <6 months is prognostic for metastasis and prostate cancer-specific death for patients receiving salvage radiation therapy post radical prostatectomy.Impact of a genomic classifier of metastatic risk on postoperative treatment recommendations for prostate cancer patients: a report from the DECIDE study group.Circulating microRNAs predict biochemical recurrence in prostate cancer patients.The natural history and predictors of outcome following biochemical relapse in the dose escalation era for prostate cancer patients undergoing definitive external beam radiotherapy.Cancer-specific survival after metastasis following primary radical prostatectomy compared with radiation therapy in prostate cancer patients: results of a population-based, propensity score-matched analysis.Genetic variants of the CYP1B1 gene as predictors of biochemical recurrence after radical prostatectomy in localized prostate cancer patients.Decreased TSPAN1 promotes prostate cancer progression and is a marker for early biochemical recurrence after radical prostatectomy.Statin use in relation to prostate cancer outcomes in a population-based patient cohort study.High-intensity focused ultrasound therapy for prostate cancer.Statin use and the risk of biochemical recurrence of prostate cancer after definitive local therapy: a meta-analysis of eight cohort studies.Impact of NADiA ProsVue PSA slope on secondary treatment decisions after radical prostatectomy.Adjuvant versus salvage radiotherapy following radical prostatectomy: do the AUA/ASTRO guidelines have all the answers?Nuclear Shape and Architecture in Benign Fields Predict Biochemical Recurrence in Prostate Cancer Patients Following Radical Prostatectomy: Preliminary Findings.The value of multimodality imaging in the investigation of a PSA recurrence after radical prostatectomy in the Irish hospital setting.Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features.Early salvage radiation therapy post-prostatectomy: key considerations.Combined Whole Body and Multiparametric Prostate Magnetic Resonance Imaging as a 1-Step Approach to the Simultaneous Assessment of Local Recurrence and Metastatic Disease after Radical Prostatectomy.A risk-adjusted definition of biochemical recurrence after radical prostatectomy.A Cost-Utility Analysis of Prostate Cancer Screening in Australia.Weight change, obesity and risk of prostate cancer progression among men with clinically localized prostate cancer.Prediction of biochemical recurrence after radical prostatectomy with PI-RADS version 2 in prostate cancers: initial results.Value of 111 In-prostate-specific membrane antigen (PSMA)-radioguided surgery for salvage lymphadenectomy in recurrent prostate cancer: correlation with histopathology and clinical follow-up.Genetic variants in the TEP1 gene are associated with prostate cancer risk and recurrence.Identification and Validation of a Five MicroRNA Signature Predictive of Prostate Cancer Recurrence and Metastasis: A Cohort StudyMultisite Experience of the Safety, Detection Rate and Diagnostic Performance of Fluciclovine (18F) Positron Emission Tomography/Computerized Tomography Imaging in the Staging of Biochemically Recurrent Prostate CancerSalvage pelvic lymph node dissection in recurrent prostate cancer: surgical and early oncological outcome.Prostate-specific antigen measured 3 months after radical prostatectomy as a new predictor of biochemical recurrence.
P2860
Q26744531-0AD4E514-1BF2-4ADD-9038-96416787AD4EQ30859743-C2CD136B-8713-4A82-975F-66011E0FAB0CQ30938412-712F5C86-D88B-470E-AAAD-6C22CE26DFDCQ30976248-42F5DDBA-D1CD-4595-B2CB-F4E8F1CC9F97Q33898869-09D8816C-DE70-4E23-AC5B-2469E50B6A3BQ34372567-50A27152-9398-4221-9D4D-5F7056830564Q34458237-4D1F44ED-B9E0-45B3-B79C-BF975AE8250AQ35827582-B075E983-F6C2-4048-9891-AC59F5D754E0Q36100502-89DEDFD4-2BC7-4C00-AED6-1DF025D01A83Q36455680-C950E32D-4F49-47F1-B055-B31BEEB9845EQ36544815-7569EA03-41D9-44FC-A13D-1918C9AB3F87Q36706936-8E77E515-2715-45AB-AC9C-D3C461BCD29AQ36738996-93FB8398-019D-489A-9DD2-1F0B2FF0C46AQ37033549-226712B2-0CDB-4D7D-B2BC-8A2AC33A476AQ37038406-04412F05-2EED-4B70-AE38-C49346CC06C1Q37081843-8F4E54EE-F0FC-410B-AF98-1E26E191AB66Q37213044-CFA27175-8E48-4E4F-9B3E-FD4E626CE11AQ37302853-0E3E51F1-18A6-4AB9-AE68-E67A94E73433Q37327993-0C5B7A6F-B6FE-43CB-B684-FBD5D57C60C3Q37665314-F79E579E-E593-4391-A6A5-FF342E0A1232Q37667939-214AC255-7044-46E8-BA40-6AA79F53DF1BQ37970412-59577D9E-05E9-4E87-B8B1-BFE4ADCD6C69Q38047044-FAC20136-D979-4F88-90F3-8925F029CE0EQ38229941-DF28CF87-A8B1-490E-8953-FA49BE7261C9Q38264782-3A9CBD7A-12AF-4BA6-825F-6063BA6A7BF1Q38650310-6D666967-98D5-4A9B-BD6A-E9C0DD42B038Q38726659-53D445CC-3C6E-439C-85DE-869037AA5A03Q38841717-C6F5AC88-D17A-4929-8C17-15FE469CB9A9Q38844315-5A223DCB-70FB-450D-8B56-00FEF3B6DC5EQ39143177-A8355B52-4023-4746-9981-832F02D1E064Q39234684-27CABF49-8440-495A-8AC2-0182A594973CQ39273026-5052638A-D5F3-4947-BB97-42274A0B57B2Q40185822-6708EEAD-36A4-419D-8541-864659CA1971Q40330198-5A3CA535-A67C-4582-AF8E-0DA39C60365EQ40468376-4ACC2C5B-3328-44FE-A223-776A7A094BBAQ40665254-095BEB30-D096-4B03-A490-7E8029680E98Q41871428-8F6C94EE-EA94-4029-85BC-75F7990882A7Q42379563-105A2BB8-3AB9-4038-919D-A247E367D610Q42785526-26007499-F0F6-46D0-B3E2-5E8964764896Q43429179-879E0080-4D5D-497E-A217-8E40CEAA7B43
P2860
Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Long-term risk of clinical pro ...... me from surgery to recurrence.
@en
Long-term risk of clinical pro ...... me from surgery to recurrence.
@nl
type
label
Long-term risk of clinical pro ...... me from surgery to recurrence.
@en
Long-term risk of clinical pro ...... me from surgery to recurrence.
@nl
prefLabel
Long-term risk of clinical pro ...... me from surgery to recurrence.
@en
Long-term risk of clinical pro ...... me from surgery to recurrence.
@nl
P2093
P1433
P1476
Long-term risk of clinical pro ...... me from surgery to recurrence.
@en
P2093
Eric J Bergstralh
Laureano J Rangel
Matthew K Tollefson
Michael L Blute
R Houston Thompson
R Jeffrey Karnes
Stephen A Boorjian
P304
P356
10.1016/J.EURURO.2011.02.026
P407
P577
2011-02-22T00:00:00Z